Thrombosis rates in patients with cancer receiving immune checkpoint inhibitors: results from a prospective cohort study

Hamostaseologie 2024; 44(S 01): S26-S27
DOI: 10.1055/s-0044-1779095

Abstracts

Topics

T-06. Cancer and thrombosis

C. Englisch

¹Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria

,

F. Moik

¹Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria

²Medical University of Graz, Department of Internal Medicine, Division of Oncology, Graz, Austria

,

D. Steiner

¹Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria

,

A. Starzer

³Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology, Vienna, Austria

,

A. Berghoff

³Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology, Vienna, Austria

,

M. Preusser

³Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology, Vienna, Austria

,

I. Pabinger

¹Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria

,

C. Ay

¹Medical University of Vienna, Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Vienna, Austria